” We have made
The EMBOLD study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, efficacy (motor seizure frequency), and pharmacokinetics (PK) of
SCN2A-DEE is a monogenic seizure disorder caused by a variant of the SCN2A gene. The SCN2A gene is essential for the formation of sodium channel proteins in the brain, which control the flow of sodium ions into neurons. This movement of sodium ions is a major part of generating electrical signals called action potentials, the way cells communicate. SCN2A-DEE exhibits a wide range of phenotypes. Early-onset SCN2A-DEE presents before three months and can have a profound impact on patients, including drug-resistant seizures, significant cognitive impairment, movement disorders such as dystonia or ataxia, and in other body systems such as gastrointestinal or ocular. There is currently no approved treatment for SCN2A-DEE, and the standard of care usually involves a regimen of many concurrent antiepileptic drugs as well as drugs for comorbidities. Despite these interventions, more than 70% of early-onset SCN2A-DEE patients live with uncontrolled seizures and approximately 75% live with severe intellectual disability.
SCN8A-DEE is a rare developmental and epileptic encephalopathy caused by a variant of the SCN8A gene. The SCN8A gene is essential for the formation of sodium channel proteins in the brain, which control the tracking of sodium ions in neurons. This movement of sodium ions is a major part of generating electrical signals called action potentials, the way cells communicate. Patients suffer from recurrent, usually drug-resistant seizures that begin on the first day of life. Seizures can be of several different types, up to dozens per day, with poor response to current treatment options. Patients with SCN8A-DEE have significant cognitive impairment, ranging from moderate to severe; often movement disorders, such as dystonia or ataxia; and problems in other bodily systems such as gastrointestinal or ocular. SCN8A-DEE patients may also exhibit autonomic features such as increases or decreases in heart rate, abnormal breathing, and cyanosis.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including , without limitation, statements regarding Praxis’ forecast clinical trial schedule, our expectations, plans and timeline for Praxis clinical data and the development of Praxis’ product candidates, including clinical trial design and therapeutic potential of Praxis’ product candidates, and other statements containing the words “anticipate”, “believe”, “continue”, “could”, “endeavour”, “estimate”, “expect” , “anticipate”, “intend”, “may”, “could”, “plan”, “potential”, “predict”, “project”, “seek”, “should”, “target”, ” will be” or “would be” and expre statements that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.
The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the uncertainties inherent in clinical trials ; the expected timing of submissions for regulatory approval or review by governmental authorities; risks, uncertainties and assumptions regarding the impact of the continuing COVID-19 pandemic on Praxis’ business, operations, strategy, objectives and anticipated timelines, Praxis’ ability to initiate, register, conduct or complete ongoing and planned clinical trials and Praxis’ timelines for regulatory submissions; and other risks relating to Praxis’ programs and operations, as described in its Quarterly Report on Form 10-Q for the quarter ended
Alex Kane Praxis Precision Medicinesinvestors@praxismedicines.com 617-300-8481 Media Contact: Ian Stone Canale CommunicationsIan.firstname.lastname@example.org 619-849-5388
2022 GlobeNewswire, Inc., source
#Praxis #Precision #Medicines #Advance #Phase #PRAX562 #Study #Pediatric #Patients #Developmental #Encephalopathies #Epilepsy #MarketScreener